Pharmacological Treatment of Chronic Stable Angina Pectoris, 2015 Current Cardiovascular Therapy Series

This book is intended for general cardiologists and other physicians involved in the care of patients with chronic stable angina (CSA). The goal of this book is to update clinicians on recent data on the medical management of patients with CSA. Ischemic heart disease remains a major public health problem. Chronic stable angina is the initial manifestation of ischemic heart disease in approximately one half of patients. Stable coronary artery disease is generally characterized by episodes of reversible myocardial demand/supply mismatch, related to ischaemia or hypoxia, which are usually inducible by exercise, emotion or other stress and reproducible?but, which may also be occurring spontaneously. Such episodes of ischaemia/hypoxia are commonly associated with transient chest discomfort (angina pectoris). The aim of the management of CSA is to reduce symptoms and improve prognosis. The management of these patients encompasses lifestyle modification, control of coronary artery disease risk factors, evidence-based pharmacological therapy and patient education. All patients with stable angina should be offered optimal medical treatment, defined as one or two anti-anginal drugs as necessary, plus drugs for secondary prevention of cardiovascular disease. Regarding the role of revascularization, randomised trials provide compelling evidence that myocardial revascularisation by coronary artery bypass grafting or by percutaneous coronary intervention improves symptoms of angina relative to continued medical treatment.

​ Mechanisms of angina.- An overview of treatment and guidelines – ESC /ACC-AHA/ NICE.- Beta-blockers.- Calcium channel blockers.- Nitrates.- Nicorandil.- Ivabradine. Trimetazidine.- Ranolazine.- New antianginal drugs still not available for clinical use.- Medical therapy versus revascularization in the management of stable angina pectoris.

Dr Pablo Avanzas is a Consultant in Interventional Cardiology at Hospital Universitario Central de Asturias in Oviedo, Spain. Dr Juan Carlos Kaski is Head of the Cardiovascular Sciences Research Centre at St George's University of London (UK) and President of the International Society of Cardiovascular Pharmacotherapy.